A5032478325- Hematopoietic Stem Cell Transplantation
- Renal Transplantation Outcomes and Treatments
- Acute Lymphoblastic Leukemia research
- T-cell and B-cell Immunology
- Immune Cell Function and Interaction
- Acute Myeloid Leukemia Research
- Childhood Cancer Survivors' Quality of Life
- Palliative Care and End-of-Life Issues
- Polyomavirus and related diseases
- Organ Transplantation Techniques and Outcomes
- Transplantation: Methods and Outcomes
- Mesenchymal stem cell research
- Organ Donation and Transplantation
- Cancer Genomics and Diagnostics
- Chronic Myeloid Leukemia Treatments
- Neutropenia and Cancer Infections
- CAR-T cell therapy research
- Multiple Myeloma Research and Treatments
- Chronic Lymphocytic Leukemia Research
- Cancer survivorship and care
- Immunotherapy and Immune Responses
- Biomedical Ethics and Regulation
- Hemoglobinopathies and Related Disorders
- Ethics and Legal Issues in Pediatric Healthcare
- Immunodeficiency and Autoimmune Disorders
Medical College of Wisconsin
2016-2025
Royal Astronomical Society
2022-2024
Memorial Sloan Kettering Cancer Center
2024
Areté Associates (United States)
2024
Dana-Farber Cancer Institute
2024
Danbury Hospital
2023
John Wiley & Sons (United States)
2022-2023
John Wiley & Sons (United Kingdom)
2022-2023
National Marrow Donor Program
2016-2022
Froedtert Hospital
2015-2021
Several international recommendations address the assessment of graft-versus-host disease (GvHD) after hematopoietic cell transplantation (HCT). This position statement by GvHD experts from European Society for Blood and Marrow Transplantation (EBMT), National Institutes Health (NIH) Center International Transplant Research (CIBMTR) reviews existing guidelines both acute chronic GvHD, addresses potential confusions that arise in daily practice proposes consensus definitions many key terms....
Summary A joint working group established by the H aemato‐oncology subgroup of B ritish C ommittee for S tandards in aematology ( BCSH ) and ociety one M arrow T ransplantation BSBMT has reviewed available literature made recommendations diagnosis management acute graft‐versus‐host disease. This guideline includes grading disease as well primary treatment options patients with steroid‐refractory The goal should be effective control while minimizing risk toxicity relapse.
Hematopoietic cell transplantation (HCT) is curative for hematologic disorders, but outcomes are historically inferior when using HLA-mismatched donors. Despite unrelated donor registries listing > 38 million volunteers, 25%-80% of US patients lack an HLA-matched donor, with significant disparity across ethnic groups. We hypothesized that HCT a mismatched (MMUD) post-transplant cyclophosphamide (PTCy), novel strategy successful in overcoming genetic related donors, would be feasible and...
The use of HLA-mismatched donors could enable more patients with ethnically diverse backgrounds to receive allogeneic hematopoietic cell transplantation (HCT) in the United States. However, real-world trends and outcomes following mismatched donor HCT for remain largely undefined. We conducted this study determine whether platforms have increased access patients, particularly through application novel graft-versus-host disease (GVHD) prophylaxis regimens, are comparable those non-Hispanic...
PURPOSEAccess to allogeneic hematopoietic cell transplantation (HCT) remains limited among persons of non-European ancestry if human leukocyte antigen (HLA) matching is required. We evaluated whether post-transplant cyclophosphamide (PTCy)-based graft-versus-host disease (GVHD) prophylaxis improved HCT outcomes with HLA-matched unrelated donor (MUD) and mismatched (MMUD) when compared calcineurin inhibitor (CNI)-based prophylaxis.METHODSThree-year overall survival (OS) GVHD-free,...
CD19-targeted chimeric antigen receptor (CAR) modified T cell immunotherapy is a novel treatment with promising results in patients relapsed/refractory lymphoid malignancies. CAR therapy has known early toxicities of cytokine release syndrome and neurotoxicity, but little about long-term neuropsychiatric adverse effects. We have used patient-reported outcomes, including Patient-Reported Outcomes Measurement Information System (PROMIS) measures, to assess other outcomes 40 relapse/refractory...
Donor factors, in addition to HLA matching status, have been associated with recipient survival unrelated donor (URD) hematopoietic cell transplantation (HCT); however, there is no hierarchical algorithm that weights the characteristics of individual donors against each other a quantitative manner facilitate selection. The goal this study was develop and validate selection score prioritizes better 8/8 HLA-matched URDs. Two separate patient/donor cohorts, first receiving HCT between 1999 2011...
<h3>Importance</h3> Bone marrow or peripheral blood from unrelated donors may be used for hematopoietic cell transplantation. Information about the relative success of transplantation with these 2 graft sources would help physicians and patients choose between them. <h3>Objective</h3> To compare patient-reported outcomes randomized to receive 1 types donor <h3>Design, Setting, Participants</h3> This follow-up a clinical trial included English- Spanish-speaking 16 years older participating in...
HLA matching at an allelic-level resolution for volunteer unrelated donor (VUD) hematopoietic cell transplantation (HCT) results in improved survival and fewer post-transplant complications. Limitations typing technologies used the hyperpolymorphic genes have meant that variations outside of antigen recognition domain (ARD) not been previously characterized HCT. Our aim was to explore extent diversity ARD determine impact this on transplant outcome. Eight hundred ninety-one VUD-HCT donors...
Hematopoietic cell transplantation (HCT) has been successfully used to treat many malignant and nonmalignant conditions. As supportive care, donor selection, treatment modalities evolve, documenting HCT trends outcomes is critical. This report from the Center for International Blood Marrow Transplant Research (CIBMTR) provides an update on current activity survival rates in United States. Additional data use of adolescent young adult (AYA) population are included. AYA patients more...
Severe hepatic veno‐occlusive disease (VOD) is a recognized complication of autologous and allogeneic stem cell transplantation (SCT) that often fatal. Defibrotide (DF) polydeoxyribonucleotide has been found to have anti‐thrombotic, anti‐ischaemic thrombolytic properties without causing significant anticoagulation. Preliminary studies demonstrated activity for DF in the treatment VOD, with minimal associated toxicity. In present study, 40 patients who fulfilled established criteria VOD were...